11.00-12.00

Start of the meeting: coffee, tea

12.00-14.30

EUROBONET

12.00-12.20

Preclinical models to select new drugs for bone tumours. P Hogendoorn, Leiden, The Netherlands

12.20-12.45

Clinical and translational drug development in bone tumours. B. Hassan, Oxford, UK

12.45-13.05

New targets in chondrosarcoma. J Bovee, Leiden, The Netherlands

13.05-13.25

Angiogenesis in bone tumours. P Rutkowski, Warschau, Poland (to be confirmed)

13.25-13.45

Giant cell tumour and PNVS, J-Y Blay, Lyon, France

13.45-14.10

Where surgery ends. M. Gibbons, Oxford, UK

14.10-14.30

Zoledronate in bone tumours. S Piperno, France (to be confirmed)

14.30-15.00

EURAMOS 2. Discussion on the design of a new study in osteosarcoma. J Whelan, London, UK

15.00-15.30

Coffee/Tea/snack

15.30-16.30

Imaging/Response

15.30-15.50

PET/MRI in Ewing/osteosarcomas. A van de Luijtgaarden, Nijmegen, The Netherlands

15.50-16.20

PET as a prognostic marker for desmoids. B Kasper, Mannheim, Germany

16.20-17.00

Dynamic contrast enhanced MRI. H Bloem, Leiden, The Netherlands

16.30-18.00

Meetings subcommittees

18.30

drinks, Prentenkabinet, Leiden (www.prentenkabinet.nl)

19.30

dinner, Prentenkabinet, Leiden (www.prentenkabinet.nl)

9.00-10.15

Business meeting

10.15-10.30

Coffee break

10.30-12.30

General meeting, including study reports

12.30-13.00

Lunch

13.00-14.00

Continuation general meeting and closure